Skip to main content

Table 4 Effects of FGFR4 deficiency on glucose metabolic pathways in breasts and breast tumor

From: Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations

Proteins

WT

KO

Tg

KO-Tg

1. Glucose metabolism:

    

Eno3

1

0.18 (0.04) *

0.10 (0.02)

0.03 (0.002)

Pgam2

1

0.22 (0.03)

0.11 (0.02)

0.05 (0.01)

Gck

1

0.45 (0.07)

0.41 (0.07)

0.07 (0.02)

Fbp2

1

2.23 (0.37)

0.07 (0.01)

0.55 (0.04)

G6pc

1

0.04 (0.003)

1.43 (0.11)

0.13 (0.03)

Pck1

1

3.39 (0.44)

0.01 (0.001)

0.12 (0.02)

Pdk4

1

6.86 (0.57)

0.15 (0.03)

1.02 (0.14)

2. Glycogen metabolism

    

Gys2

1

2.79 (0.19)

0.02 (0.003)

0.12 (0.03)

Pygm

1

0.22 (0.03)

0.08 (0.01)

0.04 (0.002)

  1. *Data are mean (SD): p <0.05 (n = 4 for each group). FGFR, fibroblast growth factor receptor; KO, FGFR4 knockout mice; Tg, MMTV-TGFα transgenic mice; KO-Tg, FGFR4−/−: MMTV-TGFα bigenic mice.